Investors

Press Releases

 
Press Releases
  Date Title View
Aug 15, 2017
JERSEY CITY, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, commends the Centers for Disease Control and Prevention (CDC) for organizing the first Fungal Disease Awareness We...
Aug 14, 2017
Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue Positive efficacy data reported from proof-of-concept Phase 2 VVC study JERSEY CITY, N.J., Aug. 14, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology comp...
Aug 8, 2017
Dosing Initiated in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Recent Data Publications Showcase Broad and Potent Activity of SCY-078 Against Multiple Fungal Species Including Candida auris JERSEY CITY, N...
Aug 7, 2017
JERSEY CITY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental B...
Aug 3, 2017
Study initiation marks important milestone following promising clinical results in previous Phase 2 study Additional pre-clinical results for VVC to be presented at upcoming 2017 IDSOG Annual Meeting JERSEY CITY, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- SCY...
Jun 15, 2017
JERSEY CITY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a study evaluating the activity of SCY-078 against three hundred a...
Jun 13, 2017
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer, will participate in a panel at the ...
Jun 5, 2017
Potent and broad activity of SCY-078 shown against more than 300 clinical Candida isolates    Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile  JERSEY CITY, N.J., June 05, 2017 (GLOBE...
May 24, 2017
JERSEY CITY, N.J., May 24, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies ...
May 11, 2017
SCY-078 may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC Multiple studies confirm SCY-078's broad spectrum of activity against Candida species, including resistant strains JERSEY CITY, N.J., May 11, 2017 (G...
1
... NextLast
= add release to Briefcase